Massive Bio's multidisciplinary team is has in-depth business and healthcare experience consisting of oncologists, molecular diagnostic scientists, reimbursement experts, and data scientists.
Dr. Selin Kurnaz, CEO and cofounder of Massive Bio. After emigrating from Turkey and completing a PhD at the University of Michigan, receiving multiple engineering degrees, Selin spent more than a decade specializing in delivering revenue enhancement, margin optimization and capital efficiency improvements for Healthcare and Life Science companies. Her startup, Massive Bio, brings the latest knowledge in cancer care to patients treated at community practices in the US and worldwide. Selin has written and spoke extensively about life sciences in tech and how to deliver information in creative ways. Massive Bio is an alumni of eLab and PhilipsHealthworks Precision Cancer Care start-up acceleration programs.
Dr. Arturo Loaiza-Bonilla is the current Vice Chairman of the Department of Medical Oncology at Cancer Treatment Centers of America (CTCA), Chief of Medical Oncology and Medical Director of Research at CTCA - Philadelphia. A dedicated practicing clinician, international speaker, and precision oncology expert with experience at the Abramson Cancer Center of the University of Pennsylvania, University of Miami, Johns Hopkins and the National Institutes of Health, his major interest focuses in the field of innovative approaches to optimize clinical workflows and trial design (adaptive trials, synthetic control arms, basket trials), and matching for oncology patients to phase 1-3 clinical and translational research cancer trials, integrating next-generation personalized molecular diagnostics, immunotherapy, biomarkers, previous therapies, and the patient's overall status in treatment decision making, with special interest in Artificial Intelligence-based / machine and deep learning platforms. Dr. Loaiza-Bonilla is Principal and co-investigator on several Phase I/III clinical trials in several malignancies, with emphasis in new targeted therapies, novel molecules and immunotherapy, tailored to specific tumor type, its genomics and protein expression profiles. He is also a passionate advocate for improved access to medical care, precision oncology, technology, wearables, medical education, block chain, organized medicine leadership and health policy, having been awarded the 'Top 40 Under 40' award by the Philadelphia Business Journal, Castle Connolly’s Top Doctor listing, AMA Foundation Leadership Award, Fellowship of the American College of Physicians, and holding a Master in Medical Education (M.S.Ed) degree from the University of Pennsylvania. He has held several leadership positions in state and medical societies, including his tenure as executive board member of the Pennsylvania Society of Oncology and Hematology (ASCO State Affiliate), and his role as President of the Board of Directors of the Global Alliance for Patient Access.
Dr. Belisario A. Arango is the medical director of the Cancer Center and the Coagulation/Thrombosis Clinic at Chippewa County War Memorial Hospital and is affiliated with Helen Newberry Joy Hospital and Mackinac Straits Hospital and Health Center. In addition, Dr. Arango serves as director of the Continuing Medical Education for providers at War Memorial Hospital. As a solo practitioner, Dr. Arango specializes in providing both hematology and medical oncology care for the majority of patients who reside in the Eastern Upper Peninsula of Michigan. Prior to completing his internal medicine residency and hematology/oncology fellowship, Dr. Arango completed 2 years of medical oncology research at The University of Miami Sylvester Comprehensive Care Center/Jackson Memorial Hospital with a focus on genitourinary malignancies and sarcomas. Dr. Arango has authored multiple articles in peer-reviewed journals and has presented at international medical oncology conferences. Dr. Arango practices evidence-based medicine and believes that cancer care requires a multi-disciplinary team approach. In an era of rapid developments in cancer care knowledge, Dr. Arango has been instrumental in bringing precision medical oncology care to patients at community hospitals that was otherwise inaccessible to them unless they were evaluated at a tertiary institution. Dr. Arango’s philosophy is to take care of cancer patients as if they were his own family members. He goes above and beyond what is necessary to deliver optimal and state of the art cancer care for his patients by utilizing medical technology and collaborating with different institutions in the region.
Jason Freedman, MD, MSCE is a Board Certified Pediatric Oncologist who graduated with honors from Cornell University and received his medical degree Magna Cum Laude from Upstate Medical University in Syracuse, NY. Dr. Freedman completed his residency in Pediatrics at the Children’s Hospital of NY-Presbyterian (Columbia University) and served as Pediatric Chief Resident, thereafter. He completed fellowship training in Pediatric Hematology/Oncology at Children’s Hospital of Philadelphia (CHOP), during which time he earned a Master’s of Science in Clinical Epidemiology (MSCE) from the University of Pennsylvania. Dr. Freedman has received numerous awards and honors including induction into the Alpha Omega Alpha medical honor society, and nominations into the President’s Circle of Excellence and Attending of the Year at the Children’s Hospital of NY-Presbyterian. During fellowship at The Children’s Hospital of Philadelphia, he was the recipient of the William Potash Fellow Teacher of the Year for his commitment to resident education and clinical excellence. As a faculty member at PENN/CHOP, he has earned a Distinguished Teaching Award and was selected for the early career faculty honor roll. Dr. Freedman is an attending physician in Oncology at CHOP, where he also has administrative and teaching responsibilities. Dr. Freedman’s clinical focus is blood and marrow transplantation and hematologic malignancies. He has a particular interest in quality improvement and supportive care, and serves on several national committees. Dr. Freedman has authored several textbook chapters and peer-reviewed articles on the care of children with cancer and has contributed to the development of clinical guidelines to standardize management of symptoms associated with cancer therapy.
Mr. Culcuoglu leads operational strategy, global business initiatives, product and technology development at Massive Bio. Mr. Culcuoglu has developed several products over the past 20 years, primarily for the financial, media and health industry. A serial entrepreneur, Mr. Culcuoglu co-founded startups, where he also led business and sales operations as well technology and product development. Mr. Culcuoglu took senior roles at Thomson Reuters, Mubasher, KPMG, Sabrient Systems, Anadolu Agency, Merrill Lynch and Smeal College. Mr. Culcuoglu is an active board member in multiple start-ups and an owner of a media company. In addition, Mr. Culcuoglu holds an MBA degree from Pennsylvania State University and MA degree from University of Maastricht.
Mr. Hecht is Massive Bio's Chief Financial Officer and co-founder of multiple companies. He has extensive experience working with high-growth startups on entrepreneurial finance matters, including capital markets, incentives, and governance. An accomplished entrepreneur, executive, and advisor, Joshua has played an integral role in building many technology-focused businesses and working with some of the largest companies in the world on high-profile M&A transactions. He holds a BA from Cornell University and an MBA from Columbia Business School.
Kristin Johnston is an Oncology Certified Registered Nurse, and is Massive Bio's Chief Nursing Officer. She has more than a decade of experience in helping cancer patients explore options and has personally guided thousands of patients through the clinical trial decision and enrollment process. Her role is to answer clinical questions and ensure patients have the support they need throughout their partnership with Massive Bio.